期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性硬化诊断与治疗进展 被引量：17

Progress in the diagnosis and treatment of multiple sclerosis
下载PDF
导出
摘要 随着越来越多的疾病修正药物应用于临床,多发性硬化的治疗已向前迈出了可喜的一步,同时也为患者提供了更多的选择。本文重点介绍多发性硬化当前临床研究热点,包括临床表现、辅助检查、诊断标准和治疗进展等内容。。 The growing number of disease modifying drugs（DMDs） approved for multiple sclerosis（MS） treatment is a significant step forward and provides new options for MS patients. This articlesummarizes the clinical research highlights of MS, including clinical manifestations, accessory examinations,diagnostic criteria and progress of treatment.
作者 侯世芳 刘银红 许贤豪
机构地区 卫生部北京医院神经内科
出处 《中国现代神经疾病杂志》 CAS 2014年第10期849-853,共5页 Chinese Journal of Contemporary Neurology and Neurosurgery
关键词 多发性硬化 药物疗法 综述 Multiple sclerosis Drug therapy Review
分类号 R744.51 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献23

  • 1Deisenhammer F,Bartos A,Egg R,Gilhus NE,Giovannoni G,Rauer S,Sellebjerg F; EFNS Task Force.Guidelines on routine cerebrospinal fluid analysis:report from an EFNS task force.Eur J Neurol,2006,13:913-922.
  • 2Klawiter EC,Piccio L,Lyons JA,Mikesell R,O'Connor KC,Cross AH.Elevated intrathecal myelin oligodendrocyte glycoprotein antibodies in multiple sclerosis.Arch Neurol,2010,67:1102-1108.
  • 3Berger T,Rubner P,Schautzer F,Egg R,Ulmer H,Mayringer I,Dilitz E,Deisenhammer F,Reindl M.Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.N Engl J Med,2003,349:139-145.
  • 4Lennon VA,Kryzer TJ,Pittock SJ,Verkman AS,Hinson SR.IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.J Exp Med,2005,202:473-477.
  • 5Lovblad KO,Anzalone N,Dorfler A,Essig M,Hurwitz B,Kappos L,Lee SK,Filippi M.MR imaging in multiple sclerosis:review and recommendations for current practice.AJNR Am J Neuroradiol,2010,31:983-989.
  • 6Balashov KE,Lindzen E.Acute demyelinating lesions with restricted diffusion in multiple sclerosis.Mult Scler,2012,18:1745-1753.
  • 7Gronseth GS,Ashman EJ.Practice parameter:the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review).Report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology,2000,54:1720-1725.
  • 8Poser CM,Paty DW,Scheinberg L,McDonald WI,Davis FA,Ebers GC,Johnson KP,Sibley WA,Silberberg DH,Tourtellotte WW.New diagnostic criteria for multiple slerosis:guidelines for research protocols.Ann Neurol,1983,13:227-231.
  • 9McDonald WI,Compston A,Edan G,Goodkin D,Hartung HP,Lublin FD,McFarland HF,Paty DW,Polman CH,Reingold SC,Sandberg-Wollheim M,Sibley W,Thompson A,van den Noort S,Weinshenker BY,Wolinsky JS.Recommended diagnostic criteria for multiple sclerosis:guidelines from the international panel on the diagnosis of multiple sclerosis.Ann Neurol,2001,50:121-127.
  • 10Polman CH,Reingold SC,Banwell B,Clanet M,Cohen JA,Filippi M,Fujihara K,Havrdova E,Hutchinson M,Kappos L,Lublin FD,Montalban X,O'Connor P,Sandberg-Wollheim M,Thompson AJ,Waubant E,Weinshenker B,Wolinsky JS.Diagnostic criteria for multiple sclerosis:2010 revisions to the McDonald criteria.Ann Neurol,2011,69:292-302.

二级参考文献18

  • 1Jadad AR,Moore RA,Carroll D. Assessing the quality of reports of randomized clinical trials:is blinding necessary[J].Controlled Clinical Trials,1996.1-12.doi:10.1016/0197-2456(95)00134-4.
  • 2Murray TJ. Diagnosis and treatment of multiple sclerosis[J].British Medical Journal,2006.525-527.
  • 3DeAngelis T,Lublin F. Multiple sclerosis:new treatment trials and emerging therapeutic targets[J].Current Opinion in Neurology,2008.261-271.doi:10.1097/WCO.0b013e328300c70d.
  • 4Croxford JL,Yamamura T. Back to the future for multiple sclerosis therapy:focus on current and emerging disease-modifying therapeutic strategies[J].Immunotherapy,2009,(3):403-423.doi:10.2217/imt.09.7.
  • 5Sanford M,Lyseng-Williamson KA. Subcutaneous recombinant interferon-β-la (RebifR):a review of its use in the treatment of relapsing multiple sclerosis[J].Drugs,2011.1865-1891.
  • 6Marriott JJ,Miyasaki JM,Gronseth G. Evidence report:the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis:report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology[J].Neurology,2010.1463-1470.doi:10.1212/WNL.0b013e3181dc1ae0.
  • 7Jeffery DR,Markowitz CE,Reder AT. Fingolimod for the treatment of relapsing multiple sclerosis[J].Expert Review of Neurotherapeutics,2011.165-183.doi:10.1586/ern.10.193.
  • 8Cohen JA. How effective is intravenous immunoglobulin for the treatment of relapsing-remitting multiple sclerosis[J].Neurology,2008.588-589.
  • 9Bermel RA,Weinstock-Guttman B,Bourdette D. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis:a 15-year follow-up study[J].Multiple Sclerosis,2010.588-596.
  • 10Comi G,Martinelli V,Rodegher M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCLSe study):a randomised,double-blind,placebo-controlled trial[J].The Lancet,2009.1503-1511.doi:10.1016/S0140-6736(09)61259-9.

共引文献7

同被引文献262

引证文献17

二级引证文献64

中国现代神经疾病杂志
2014年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部